Hemab Therapeutics Holdings
COAG
28.70
+0.33
+1.16%
Hemab Therapeutics Holdings
US · COAG
#3007 by market cap
Listed 2026
28.70
+0.33
+1.16%
Live - 5344 symbols - heartbeat 7s ago
· 2026-10-08 02:52
After-hours
28.70
0.00%
Overnight
28.37
-1.15%
- Market cap
- 1.34B
- P/E (TTM)i
- -16.11
- P/Bi
- 2.95
- EPSi
- -1.45
- Div yieldi
- 0.00%
- 52W posi
- 18%
Reader sentiment
Are you bullish or bearish on COAG?
Anonymous reader poll. Unscientific, not investment advice.
About Hemab Therapeutics Holdings
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.
- Founded
- 2020
- CEO
- Mr. Benny Sorensen, M.D.,PhD
- Employees
- 72
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- hemab.com
Company profile
- Exchange
- US
- Symbol
- COAG
- Market-cap rank
- #3007
- Listing date
- 2026-05-01
- Market cap
- 1.34B
- Float cap
- 480.73M
- Shares out
- 46.71M
- Float shares
- 16.75M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-10-08 02:52:22 · For reference only, not investment advice and not tailored to your situation.